-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 PFu7FNfyG29CWB7DI3Vh1bj9vB20vHn1NBrGltB+v4nuVILqbcgkgJQZcKZ2JXYZ
 73+NI+BqhUl/AkDXktK8+Q==

<SEC-DOCUMENT>0001193125-11-023251.txt : 20110203
<SEC-HEADER>0001193125-11-023251.hdr.sgml : 20110203
<ACCEPTANCE-DATETIME>20110203171102
ACCESSION NUMBER:		0001193125-11-023251
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110203
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110203
DATE AS OF CHANGE:		20110203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			pSivida Corp.
		CENTRAL INDEX KEY:			0001314102
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				262774444
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51122
		FILM NUMBER:		11570848

	BUSINESS ADDRESS:	
		STREET 1:		400 PLEASANT STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-926-5000

	MAIL ADDRESS:	
		STREET 1:		400 PLEASANT STREET
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida LTD
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM&nbsp;8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act
of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): February&nbsp;3, 2011 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>PSIVIDA CORP. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of Registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-51122</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>26-2774444</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>400 Pleasant Street
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Watertown, MA 02472 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(617) 926-5000
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
February&nbsp;3, 2011, pSivida Corp. (&#147;pSivida&#148;) issued a press release announcing month 36, top-line results reported by pSivida&#146;s licensee, Alimera Sciences, Inc. (&#147;Alimera&#148;), from its Phase 3 FAME&#153; Study readout of
Iluvien<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> in patients with diabetic macular edema. Alimera has prepared webcast slides dated February&nbsp;3,
2011 with respect to those results. pSivida&#146;s press release and Alimera&#146;s slides are filed as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of pSivida dated February 3, 2011.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Webcast slides of Alimera dated February 3, 2011 incorporated by reference to Exhibit 99.2 of Form 8-K of Alimera furnished to the SEC on February 3, 2011.</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">pSivida Corp.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ L<SMALL>ORI</SMALL> F<SMALL>REEDMAN</SMALL></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lori Freedman</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President Corporate Affairs,</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">General Counsel &amp; Secretary</FONT></P></TD></TR></TABLE></DIV> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated:&nbsp;February&nbsp;3, 2011
</FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:0%">

<IMG SRC="g146181ex99_1pg001.jpg" ALT="LOGO"> </P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR IMMEDIATE RELEASE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>PSIVIDA ANNOUNCES POSITIVE RESULTS FROM THE 36 MONTH READOUT OF COMPLETED PHASE 3 FAME&#153; STUDY OF ILUVIEN<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> IN PATIENTS WITH DIABETIC MACULAR EDEMA </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WATERTOWN, Mass., Feb 03, 2011 (BUSINESS WIRE) &#151; pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases,
including the investigational drug ILUVIEN<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> for the treatment of Diabetic Macular Edema (DME), today announced
month 36, top-line readout results for the FAME&#153; Study prepared by its licensee, Alimera Sciences, Inc. (Alimera). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alimera previously
presented the month 24, top-line results from the now completed FAME Study. The FAME Study consisted of two 3-year, Phase 3 pivotal clinical trials (Trial A and Trial B) to assess the safety and efficacy of ILUVIEN in the treatment of DME. Patients
in the trials were randomized to receive either high dose ILUVIEN, low dose ILUVIEN or control treatment. The primary endpoint for efficacy in the trials was the difference in the percentage of patients whose best corrected visual acuity (BCVA)
improved by 15 or more letters from baseline on the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart at month 24 between the treatment and control groups. Alimera presented data for both the low and high dose patient results at 24
months. Based on these data, Alimera submitted a New Drug Application (NDA) on June&nbsp;29, 2010 for approval of only the low dose. Therefore, only the low dose data from the 36 month readout is being released by Alimera and is discussed in this
release. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alimera reported that data through month 36 for the Full Analysis Set in Trial A demonstrated statistically significant therapeutic
effects of 28.9% at month 30 (p= 0.011) and 28.4% at month 33 (p= 0.042) of ILUVIEN patients gaining 15 or more letters compared to the control group, in which fewer than 17% of patients gained 15 or more letters. The therapeutic effect was
maintained at month 36 (with 28.4% of patients gaining 15 or more letters); however, as 18.9% of the control group gained 15 or more letters, the p value increased to p=0.106. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Results from Trial B reported by Alimera were similar. Statistically significant therapeutic effects of 33.9% at month 30 (p=0.002) and 29.6% at month 33 (p=0.046) of ILUVIEN patients gaining 15 or more
letters over baseline were reported compared to the control group, which had fewer than 18% of patients making such gains. At month 36, 29.0% of ILUVIEN patients gained 15 or more letters compared with 18.9% of control patients (p=0.086).
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">By comparison, in the month 24 data earlier reported by Alimera, 26.8% of ILUVIEN patients and 14.7% of
control patients had gained 15 or more letters (p=0.029) at month 24 in Trial A. In Trial B at month 24, 30.6% of ILUVIEN patients and 17.8% of control patients (p=0.030) had gained 15 letters or greater over baseline. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As reported by Alimera, Trial A and B data combined demonstrated a statistically significant effect at week 3, and this effect was maintained throughout
the 36 months. On a combined basis, 28.7% of ILUVIEN patients and 16.2% of control patients (p = 0.002) had an improvement in BCVA of 15 letters or greater over baseline at month 24, 31.4% versus 15.1% at month 30 (p=&lt;0.001), 29.0% versus 17.3%
at month 33 (p=0.004) and 28.7% versus 18.9% at month 36 (p=0.018). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We believe this data is very promising, and look forward to the
response from the FDA. If approved, pSivida will be entitled to a $25.0 million milestone payment from Alimera and 20% of profits (as defined) on sales of ILUVIEN by Alimera,&#148; said Paul Ashton, president and CEO of pSivida. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Full Analysis Set includes 376 patients in the ILUVIEN arm and 185 patients in the control arm with data imputation employed using last observation
carried forward (LOCF) only for missing data. Data for the Full Analysis Set includes 190 patients in Trial A and 186 patients in Trial B randomized to the ILUVIEN arm. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Alimera reported safety data for all patients treated with ILUVIEN low dose and control group in the study. Increases in intraocular pressure (IOP) to 30 millimeters of mercury (<I>mmHg</I>) or greater at
any time point were reported in 18.4% of the patients by month 36 compared to 16.3% by the month 24 readout. By month 36, 4.8% of patients had undergone an incisional surgical procedure to reduce elevated pressure versus 3.7% of patients by month
24. The incidence of cataract among patients with a natural lens in their eye at the start of the trial was 81.7% at month 36, with 80% undergoing a cataract operation, compared to 80% and 74.9%, respectively, by the time of the month 24 readout.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alimera reported that the statistical significance observed in both trials at month 33 met the criteria for replication of two studies and
that Alimera will provide the 36 month safety and efficacy data to the FDA in connection with the pending NDA for ILUVIEN. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Webcast slides
prepared by Alimera containing more detailed information with respect to the 36 month data are being filed by pSivida with the Securities&nbsp;&amp; Exchange Commission on Form 8-K. The information in this press release is qualified in its entirety
by the more detailed information contained in those slides. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional data and analysis of the FAME Study will be presented by Peter
Campochiaro, M.D., on February&nbsp;12, 2011, at 1:40 p.m. at the Angiogenesis, Exudation and Degeneration 2011 Meeting in the Mandarin Oriental Hotel, Miami, FL. Dr.&nbsp;Campochiaro is a professor in the Department of Ophthalmology at The Wilmer
Eye Institute, Retina Division at Johns Hopkins. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About the FAME Study </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Alimera conducted two 36-month, Phase 3 pivotal clinical trials (collectively known as the FAME Study) for ILUVIEN involving 956 patients in sites across the United States, Canada, Europe and India to
assess the efficacy and safety of ILUVIEN with two doses of the corticosteroid fluocinolone acetonide (FA), a high and low dose, for the treatment of DME. The primary efficacy endpoint for the FAME Study was the difference in the percentage of
patients whose best corrected visual acuity improved by 15 or more letters from baseline on the ETDRS eye chart at month 24 between the treatment and control groups. The study concluded in October 2010 with the final patient visit at the three-year
data point. Alimera prepared the analyses of the data from the FAME Study. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following its NDA submission to the FDA, Alimera submitted a
Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency in the United Kingdom. Applications have also been submitted to regulatory agencies in Austria, France, Germany, Italy, Portugal and Spain.&nbsp;Based
upon the analysis of the FAME Study, all filings included the 24-month data. The FDA, in a December 2010 Complete Response Letter, requested further information, including the month 36 data from the FAME Study. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About DME </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">DME, the primary cause of
vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage of diabetic retinopathy causes swelling in the macula, the condition is called
DME. The onset of DME is painless and may go undetected by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin
Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19 percent of people with diabetes studied were diagnosed with DME. As the population of people with diabetes increases, Alimera expects the annual incidence
of diagnosed DME to increase, as well. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ILUVIEN<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ILUVIEN is an investigative, extended release
intravitreal insert that Alimera is developing for the treatment of DME.&nbsp;Each ILUVIEN insert is designed to provide a therapeutic effect of up to 36 months by delivering sustained sub-microgram levels of FA. ILUVIEN is inserted in the back of
the patient&#146;s eye to a position that takes advantage of the eye&#146;s natural fluid dynamics. The insertion device employs a 25-gauge needle, which allows for a self-sealing wound.</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About pSivida Corp. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT
STYLE="font-family:Times New Roman" SIZE="2">pSivida is a world leader in the development of tiny drug delivery products that are administered by implantation, injection or insertion and provide sustained release of drugs on a controlled and level
basis for months or years. The Company uses these systems to develop treatments for serious, unmet, medical needs. The Company&#146;s most advanced product candidate, Iluvien</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(R)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">, delivers fluocinolone acetonide (FA) for the treatment of diabetic macular edema. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are
inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. The following
are some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements: ability to obtain additional capital uncertain;
future losses; impairment of intangibles; fluctuations in the fair values of certain outstanding warrants; fluctuations in operating results; decline of royalty income from Bausch&nbsp;&amp; Lomb; Alimera&#146;s ability to obtain regulatory approval
of Iluvien including analysis of results through month 36 of the FAME Study, safety and efficacy of Iluvien, controls and specifications concerning the manufacturing, packaging and sterilization of Iluvien and cGMP at manufacturers of Iluvien;
Alimera&#146;s ability to successfully commercialize Iluvien if approved; risk/benefit profile of Iluvien; timeliness of approval, if any, of Iluvien and any limitations on uses thereof; ability to complete clinical trials and obtain regulatory
approval of other product candidates; ability to find partners to develop and market products; termination of license agreements; competition; market acceptance of products and product candidates; reduction in use of products as a result of future
publications; ability to protect intellectual property or infringement of others&#146; intellectual property; retention of key personnel; product liability; consolidation in the pharmaceutical and biotechnology industries; compliance with
environmental laws; manufacturing risks; risks and costs of international business operations; credit and financial market conditions; legislative or regulatory changes; volatility of stock price; possible dilution through exercise of outstanding
warrants and stock options or future stock issuances; possible influence by Pfizer; ability to pay any registration penalties; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. Given these
uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise
our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>In US </I></B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Martin E. Janis&nbsp;&amp; Company, Inc </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beverly Jedynak </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: +1 (312)&nbsp;943 1123
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>bjedynak@janispr.com</U> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">or
<B><I> </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>In Australia </I></B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">pSivida Corp. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Brian Leedman </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor Relations </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: +61 8 9227 8327 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>brianl@psivida.com</U> </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g146181ex99_1pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g146181ex99_1pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`7`"D`P$1``(1`0,1`?_$`+0``0``!@,!`0``````
M```````!`P8'"`D"!`H%"P$!```'`0$```````````````$"`P0&!P@%"1``
M``8!`P($!`0$!`4%`````0(#!`4&!P`1""$2,4$3"5$B%!5A<3(6@9&A(\$S
M)!>Q0E)B&*(U-AD*$0`!`@4"!`0#!08%`@<````!`@,`$00%!B$2,4$3!U%A
M<2*!%`B1H3)"%;%28B,D%O#!DC,7<D/A\8*BLJ0E_]H`#`,!``(1`Q$`/P#W
M\:0AI"("&^I%H0L`+\8B(X"8"[AOU`-Q#8?A_+4O2*==.GSA/QB0==!(`,H<
MJ8#N`&.8I`';Q_6)>@:D^70%]5EI:E?PB?W1*7$\"M,$WC978J2Z"IA#<"IJ
MIG$0V\0`IA$0VU=%+@3N*5`^!$B/(^<4^JF>AG'8(8!WV\AU32HJG,2(B=*@
MKA'/4T30TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$23G$IO$.W;XEZ#M
M^([ZD((.XJT_=EQ^,2$K"I;?8>?A&`?*CW$\&\8EG59=OU,@9000%3_;^K.6
M@JQAS%`R1[9-G%1A6TS$-W@D?U')B=02$!`=9_BG:[(LQ*:Y0-+9AKO6)3_Z
M>9TY_A\XP;).XEAQK^E*_F;@3+:C61D3K*,5,;7?W"N:9$;)&RL9QMP[(G]1
MI+1T4Z0EY.//OZ9X99^4UCFS*([;N0^@9F'_`"S?#.[M0]L<``IWYW6]#@`H
ME"5_E"T_@VSX@@DCB(\6RW/,LL2MULHI+:J8]R!,I/$)4=09<QPC->D\(\;P
MY2NK_9,A9=G1."SB4NEPFCLU%^HG%&(8/FS<B1C]>U0R@@`!U^.OJWN'<*AQ
M5/;6:>CISR;90D_ZMH,_A&64N,-,I_K5NNJ\0M0^X&,C(7#^,H!-,L/2H-@)
M"$*51%L/KAV!L`^NHHHOW;>?=N.L8J+E6U2RM]PJ)))F!K/QTUC(&Z2G;;2V
MVDA```F23+S,XN(W;HM4BHH$!-(@`!"`(B!0#H`!N([`&K$F9G%=#:6Q),Y1
M.U")X:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0B4=4I`$WCMX@'C\>@>(CM
MY:E*TB9Y#CY1,E.X@#GPC03[I7NEJ8@E)?C9QUET0RJ9`K7).16JJ+A+&C9V
MB0PU^!-W'14O3EL?N4.(&)&$'<P>L.Q.F^S/909#T\KREM0L>I:;.A<V_G,_
MR<P/S<>''FSN]WI:L+J\2QQ0<NFB75ID0C=/VB6NX<#X<(H[VT?;=4LD?"\E
MN3#!S++3QT[-1J!8?4=NI<SLWU2%XOY7HJ+OC/C&!9DR6,(G#99QW?(0+CN]
MW88I7EXCB"DHHVSTUN(`2!(2+:=/Q"6JAH.`GK*KVT[;/+I4Y-D"5+=>`4E"
MS,S)GN/D1P'&/1`DBFW12002*DBD5)%)%(A4DD4B`!$R)ID`"D(0H;``!L&V
MN5WE.A[J2WJ6>)F9'QCHA*4(82AM.Q`D)#24=G8WX?U_PU5&^6LIQ/[AP/VQ
MR#P#4PG+7C$?7C$=(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$:Y_<R
MYEH<+N+EIR!%+MULF6IP2A8ECG`$$RURFD5>Z<4;[_W6-1BR+/U@V[3"D0@_
MK#6T>S6`+[B9BS9W`3:Z8ARJ7*20@$:3X34=/2<:D[S=QF.W.#/W@.(1=*E)
M13()DK<1J0.)VZ<.9$>8SVB^*SOF'R2=7#))75EQ]CAX3)&4)&5.=V-SMDS)
M*O(*O2CE<1,[5G95)9Y(=1`[9%1/H"VNQ._F7T^`X<S9K$0W6U22PPE.G3;:
MDE2Y>8E]L<=?3;C=5G^0O7R^#JL-.%UY2IG>I9FD:^<_A'M-D;?"0MDK%+;^
MFK.3R+YRQB60%`S.`@T$R/Y55$@;-X]HJN@W*(@!166(0.O37STI:9=92.5[
MIG3H64EPSDI\DDM@_O2FHB<Y`DQ]`*F\LT5S9LE*`Y6*;"RTGBW3CVATI&H1
MOD@'A,RBNBF-L7<H]=M^FVWY^.VK(J(7LD2GQCWSH1+@8F:GB,-(1`1`.@B&
M^H$A(W*T3$)B>WG$!.4OZC`'YCMIN&GGPB(U,AQB`J)AXG+YC^H/+Q_EJ"EH
M2H)40%'E#\P3^8\!#U$PV^<O4=@ZAU$/$`U%*@H;DZ@B?P\8C(B?EQCD!BB`
M"`AL(`(=?(?`?XZ3$MWY3$LP1NY0`P#X"`_D/\-1\^41.AVGC$=0)`$SPA''
MN+T^8.OAU\=2J<0@A*B`H\(#43'".6IX1#<`\_QT)`$SPA/67.("<@!N)@`/
M'?</#4I6D)WDC9XP`FK:/Q>$1W#XAX[?Q^&IHAN3X\Y?&(Z1&&D(:0CQ+_\`
MZ`,^O<C<Q8+"K)X4]7P%2H]!5DF/^E6O=\;(V&<=*E`P@+EI7PC6Y?`2;J!_
MS:^B'TJ8JW:L+7D+P(K+G4D:C\K8D)>1F3YSCYH_5]ESEURYO&6S_24#0X<=
MRS,S_9\(WP>R9@]EB#@=1;8\0(VL.:7LOE:Q/E"@148UPNI&U1`3'V$C5G6X
MQ-4@#\I3+F$/'?7,WU#9)_<G<VJHJ92C341%.VGD%C1PI'\2M/A'4_TWXLG$
M^T]+4U0#=14SJ5JYJ:,U)!]!%\^&5N<YSRIR/SZ\7.XC1L<9B;'!#]PI1]$J
M@+R)Q0*<=TEIR2>D<NMNBARE\B!JT[J6.GPVPV'%*82?72?.5/BJH=T!_P#2
M@[1Y1CW8'):ON1FF7=PJPGH-W(VZD3R%*S)4QX;G$S]9QL4*':`!N([>8CN.
MM)QU1$=(0TA'`WB`@'7_``\=2JD9(/X28!()W\Y1B5R9Y0M<$*T:KPE%F\HY
M.R9(N8ZD4.#<I,59`&/:9^_>R"Z2Z;%BT[R@8XD'<?,`#?6Q,#[?)S%VJK+C
M7(MEBH4@O5"@5;-P]J0!*961(3($Y1HCO9WE':]-!8K7;%7O,;JN5-1)<Z1<
M2E0ZBRO:L@-I.[1)G+E%I4\Q<_EB@JCQ"QX@D8!%-!YF9DHX2((CVE5,1L!.
M_;Q`/`=9*<4[(M.D)R>YN5*="?E!L/I[YQ@C'<CZFW4)=3@%L;;`]H5<E;Q_
M];C%/6GE;REQ%#N+EF[B.@UQ]$%24L5AH&2HJQO()@=9-%:16B%6Q%5T&P'[
MCB4Q0V\1#5_;>V';[*KB:#$LG>-Y=!#++].IM*R!/:"%'4@:2GZ1CM\[]]Y\
M%I#>>Y^!-HQ"E*2_5TE7URTV2$[BA;;>@)$YJE&5UURS8T,+M,IX9HRV7GDU
M&UJ<K%992"<2O-P]A69J?5%>.2*%;'CHQV*RA!*([D$OCK6=LQRB.4*QO*ZW
M]-::6ZVZ\$[MJVMP`E,?B*93\XZ+R/-JX]NZ?-L#H#>'JIFG>88_VRIE\(4#
MIND4H5,R)U$7QBG#ART;K.VXM'*K5LJLU,;O,W652*HL@8P``&%!01+OY[:Q
MI]#3;RVV%]1I"RE*_P!X#@?CQC.[=45%704]76M="N=IT*<:G/IJ(F4SYR.G
MPCZ1Q$"F$`W$`$0`>FJ"I[3(3/AXQ?`I&JC),6QS%:;A2L87ZW8]HRV3;U6Z
ME.352QZU>$C7%TGV#)1>+KB,DJ11-DK+.BE2!02F`G=OL.VVO4LC-NKKS3V^
MXU/RM"MP!QW;NZ:>:I>7A'C7U^KH[/45UOIA57!""6VMTBX>0GYQ/Q!:;E=<
M78^MN0Z,MC2\V2I0DS;<?N'Y)1>F3[YBBXDJVM()IHD>*1;DYDA4`A0-V".I
M;O34E'=:JDM[WS%`U4.(;=E+J-I60AR7+>D!4N4XN+/45=7::6KKV?EZUVG;
M6XUQZ:U(!6W/GL42GX1<8P[#MMOTWV^&V_4?SUY+A$SS4!.7QCT9R($M#SC!
MK/O+A]ACE/P^XYMJ4UGFG*26R-&/K6M,+,5Z@2B5]&;3.TC"1[E.6-)'5],P
M'60](/F`3>&L]QO`4W_$KWD_6(-K#4V^.X.A>OE+9]\:^R3.S8\NLN,=.:+H
MIS^9X=,H$O4[HSA)U$H=/#O+M\/#_'6`H="EA/-2`8V`IN0GX+G$_5>(PTA#
M2$?FS<_[>[NW-OE?;'IA.L[S7D!JF(F.(I-J^Z3@(U$I3#T319Q)"`'EL&W3
M7UI[542;;VPL9;``-J2O3]\B95_U>)XQ\=^]E<J[=T;P],E*JQ*1/D-Q$AY<
MY#2/=:T#_:CV[ZX2##Z56H<6*NRC@2$$NQP&.XUDE_E"4-RKN!-N'GUU\WZ:
M60]X`\XD*ZE\6L@ZS2EU1(/CI'T<RFL<QCL"^]3J*7FK"TA)3H05MH3[2-0?
M=RBV7M6)(M,#6I@02BJUR*_,J(!L(E7@H)5,QN@=3=?ZZV!]2F]>:L5!_P!I
M=&G;Z)4I,AY"0$:A^B5D-=LZI2C.H5<%%<^,RD*F>9)F228V<#T`?R'\/ZZY
MU,Y>W\7*.R3*6N@C%_F9<;1C_B7R/O-*FGE?MM0POD.QUB?8F3^LB)R)K3]W
M&2+<JZ:Z!UFKI,IR@<AR;AU`0UE."VJGO>8V^V5XG3.UR$*3R*3Q!\1Y1AV;
M72IL^&W&Y42E!]JB6I*@=0H<"#Q!\QKI&K[BO@CFQR^XX83SME_W`<WXN=W?
M'5:E8"G8+BJ3!M4H0\>DDPG[I/2T/(O[/<[,BG]>_,4J#1!1?TDDB@3?6WLN
MO^#X!E]RQZV8U15WR]6XVI=0M2@"E1T0@G:A(X"7A(C375F(X_FN;8A;K[=<
MCK*1#U&TXE+*9*(4F8*UB2EJ/$J5,F<R=8^-RHK7+KVW<=,^5E6YLYDY%4.C
M7"F,LLX>S[&TV7CK)2K/8F%=?+UF?@H>+EZ]/,EY%(Z9R`8!#?Q`!*,,0K,,
M[M7MS"ZO'Z>VW)VC?6P_2+V$+;:6L!0!`/#0F9\N<6.4V[,>UMN1EU#?JNY6
MM%4RFI9JYJ`:6XE!4C=/;J9$B1\"8S9Y18]RK+9$X[<I,'5-'),AC!I,C)T!
M[+(0LE,5B[1B"@.8IP['Z3[@W*L;Y!'N`P@(`;;;7B=N+WC5%9[]VUS"J-NI
MZXM)34J2IP(=I'"L!2@%*DL@)GS$P2(QWOCA^=5N;8OWK[<T;=WN5H0ZERA4
M6PI;-6V$!;:W"E*2@%2B`H$\@8Z0<ULY-.YNYX'9^!8@F*H*#J)=)`(#VB8J
MR3?M.40+Y:@CM9BKH54C-+2A@F8"FG`?_C%C4?4OW'9><%5VSR4UK(D>FJD4
M@G^$E_A\(I:X<V7;VJ3C'/7"[.]>Q9)1[B.N$C(1#.:B4H5R7TG7W9LF9@J6
M-$@_W1*H':'77KVKM&EFYH<PW*[/4WELGY8(6XVZI0U!2I200K3F9QC63?4]
M3U-A=HNYG;O)F<3JV]M25-H<:2`1HZA+DMD]=1+2*_Y-Y':T'@K^_N.,^6IP
M+6,QU_MW*UD$"(1];D;%",T6S-)T@Y(DC]`X,B=,Y1,40$H]0'6/X%CKU[[J
M+LF;L_,W"57\PE1*TJ=;;<5N))]RMPW;N9UF8SKO'F*,4^FQ&6=K713V\MVH
MTA;DV66'JNE3TT[?P`-*+:D@\"4\(LUS.S9FSB+EOC/RD7O%CF>),X:'PUR7
MQ\L@Q=1=+=W4$"4[-;)9-F$@U4CYEV5O(;K?3F3`H=H&4#:\P?&L>S6UWK$T
M-ML9<T''J!8!FYTUJWL?Z4R0./N_AC,,GR7(\3J<?SEYQU[&ZJE8:KFYDH;*
MT)(>VZ"94HZ\3M`,;/[?D&H47']BR/:K`QC:55*P_MT[8U')#Q[:NQL<I*N)
M,'!3>DLBHQ3[TQ*(@H(@!=]PUINWV^YW2O;LU*TLWEQX-!L`[NI.4I#[_0^$
M;QN%QME!:W+U6NH39D,EPN$^W9*<Y\^4O&>D:4<:9OY57_@ISDYYW"_6^D-<
MCTC)%RXD8X(6,10Q#C&HP+]O3+8W(I&G<.K1;G+7Z]15T*J8I@0Q"`536]+O
MCV(T/<"QX!0,)<=IU-IKG-?YSRI;TJUU"9G3SE^6-`VR_P"65V!WS/+J\II+
MR5FA;!(#3:2=JTC\I5H`1KH3%0Y;YEY]QM[9'#:]4:Q-)ODCRA-@#$L+D*XL
MVSUK%VW*C`II2]2T:BDW8O7;5%$YDTA(5(55`.)![>P8V?`+!=^ZU_HGVU_V
MI9'*U]3+:BE2FF'5)2V-0=HT''@(KW?/<AM7:K'JMEQ(RF]-T;`>7[DI<>:2
MHK5,*&X\9RXSYQ=YC[>')AZU0=7#W2.8CFR*ID-+*U,N.*S7?K#E`5@B(8M;
M<BR8$5,()E,<Q^WQ'7@.=TL5IW%MT&'6TT74]A<DMP)&DE*)F9ZG7A/2/9IN
MUV6O(0Y7Y;<_U`-R6&Y]/>9F8!(X3D-!H(P/R5B#/>$O<^]LNG9<Y!S_`"3I
M3JT9DE<:W*\P\-$9+KSP]#<(6NJV)]`I-HZRQ&R+-RR<F12<)]RR9Q,!2B.S
M,?O5@OW:C+JZTVIBVU@%/O#3JB@@AV0""9>/`:'UC7=[L^0V#NKBMOO-R7<:
M)1>V*=;`4E6YO@N4PHZ<]1+A&5W*EUG:R<H+)"Y'Y[5S@SQ:@J36AQJ6F7O%
MT1E3)MOD-S61Y8$+B969A8:/4,!6QB(^DH4``/$3!@N$HQ^@PZCK;=CCF29$
MZI8?4IFJ+3:1^%*"VCIDD`<-1/7PC-<L=R2XYA54URR)G';!3)3TDI>I>HZ3
M^9:5KW@<QN'D!Q,6J98^AIYP,7B#WX<DR^1G22I:O$V#)^";=$2,MVC]$R>P
M!(]LM)).77:0R:)_6,!A[`$=@U[[MT6MA"KQVZ336M2@%*0R^AQ`YG>$SF/6
M7B><8^BUNM.N)M'<%=3>2DK2AQUE3:I"<@E"BD`^`!YZ1GI[8O)K(7*WB=6L
MCY5+'*9)@KC?,8763A6A8V*L$YCVPN(12QLHPAS)QZ<NU33551+L4BW?V@!=
M@UK#NMC=OQ/-W[7:4N-VTL-.(0O=N1U64N%)W25HI1`GK(#4\8VEVIR.YY7A
M35TO"T+NB:EUM:D:)5TG2@$2`&J`DG0`S)C89N/9XC\/$=_YZUS)70_BE&R9
MCJ>4_P#*/S4.<$`^KW,7E9!/DSIO6^<<F%,DH($$3/;"_>H@("`#VJMG*9RC
M^/77UV[4OHKNUMG4#[A:FTH\U:[@KTTE*4?''NY3JHNY=V84-&JX[CX)21(^
MLYS^Z/=;`OT\M>VQ4I6'5^K)9>*]0D$?2."QU%VM'C%G20&#<!5(X9*)F#R,
M4=?.E+:<8[V.LN2Z+%Z>1KI^)TI3/X&<?12\,N9;].R2-7ZBQL.>WA-*&UJ`
MG/02(C'SVR[<G$S-\H;A0J9;`QC;'%@<3`59[$F59229$M_E549.T5!_[4_R
MUL[ZCK2\Z*&](F6F$EI>FDES<!]9F7IYQHWZ0[P*!ZYXVX0E#Q0ZT#Q*DA*%
M#PEQ/CIQC<(4XF*(CV^'7X;#_'X:Y40I>S>L>X\`/N^,=TK*"2B8V@:QA_SY
M$/\`P?Y9]?E#C_E3KY=*C)#N'Q+K-^V.G<&UK,Y_J"-#PXB,%[CI/_'-TV[2
MG]/<X>AC5?P*]T[C?A7B%QTQ/R"0R=B2]4K$E.B6Z#[$N0[!7[C6R12*E:N=
M0LM8@9J)E(>>ACHJB'J`J@N)TCE*)>NX^Z7:#++YG=WN6/N4-2W45SSA":AI
M*VU*62IM:%*W)4F?/[HU)VU[Q8K:<&M%KO[=91O,4#+:%+8=+;J4-I2EQ"DI
MD0H"8Y>!BG>?_-'&WN#8,6X=\.(')^8\C9GN%`CWTFVQ1?:S4J%6X2WQ5BFK
M1;;1;(6#C&C%JUBA`"E$X]1WV^4#4NW6#7'MED[>9YD[1TM)0TSQ2CKH4Z\X
MMM2`D)0K5/N,^9,I1;=T,YH.XU@_L?#J>LJJVM>9ZBRRM#*&FW4N&9*0J9*1
M^8`"-B7)>?RW@:\\;,E0*&0[3A*@0LI5<Q5N@I.)!5R)HEM'P5ADZVV/W2C9
MDJ0YR"!3BD8`^(#K'<&MV,Y[;<ALM>:*FRNKJ4OT+E0L-I2D.%;R"XLA/N3H
M`3,\@8\3O5?^X?;')\4S&S4]QKNW]!3&FNE)0M%UQ:G$AMAS8E*UE+"CO,M`
M![C'VB^Y?Q7`O8YFLA(+E_S4%,47M-1!00[C)*!]H$`4)N'=L(A^.K%/8#/%
MI6A*;:[3STVUC$B/]>HCT5?65V30HH=?N[=3M&YI5NJPXD\P=K8UBUV9N?\`
MAO(F,;U0,45W*>2;M>*U-5.%KK/%]K;)*/9N.<QR"[US*1S=LBU;F<>H(")A
M/V@4"COK*,6[)Y'8[[17O(JRUT5LI:E+Q7\Y3K5)L[MJ4H5K.4O'F3RC!>X_
MU9=OLJP>X8YA-!>;M>KE1N,-,_(U*$;WI)FXI2)IV`DB1`!''G%)9BQ9<<=^
MUA!8RGXQVXN,%#X^2E(J.07E'J+]S>XV678@BQ26,JNQ3<=BO8`E*<A@WZ;Z
MN,:RJUWOZA*J_P!&^&;8XNJVJ.U(4/EUH"M0![SJ/6/!S;MQDN,?1+28-4LK
M7DC*;<5H!4M2)U[#Y1Q)FA/M(Y2EI&Q/).):AGK`]HPWD*.1DZAD;':M4GVJ
MS<%@30DX9-%)ZBBKWE3?13LB;E`P[F371*/00UHREO5;CF5#(*!R5315BW!Y
MR43+3B%#0^(.D=G4]DI[[@=/C5S0=M1;&&C,:I5T$>XS&A2HS!TU`CS<PCCE
M)GNJXK]F6^5Z_1LMB[+;V!Y%YQ<,)9.L6WB5BES'6.AC'V18A&LH[OT<\91R
MB`*&V]!(AA-WK`3J=U_",;N=7WUMSU(H5="%4=%-/4:N"P05+;G,)21N4>/O
M7PD)\STB,VOU-2=E*^GJ0BDKC\U4G=TUT*2"$I7S.IEJ9[4@"-Z/.JJLXC@!
MRBJ-2B!:QD;QQOL'6ZY!1IE46C&/I[IA%P\1&,TQ5."*"14TD4@$QM@`N^N;
ML!N9>SNWW>N>45&X!Q;BB-QF2222.'K]L=&9Q:6VL!N5GHV4[!0%#;:0=J9"
M0V@<^!/I&L3,V'<LW7VG?;XN&-Z!/76Y<:)'C!GF8QA'LG"5NL-;H,84UDBH
MB(<$0>+3[1DY]8K42E5."9B@`F`"CN3&,HL=N[T913U=0VU07H5](V^Z9H27
MW5*2HE)`D3H%'0`@GQC4>1XM>KCV>Q9ZG8<=K+/\A4NLM_C4EEH`@!049\U`
M:SG+32,Q8SWG^":[-%6P6[)]+F#D+]RJ]IP/F!E.0KL"E%>/DD$*<[;%=LU!
M%-04U5$^XH[".L$_X%[@.5:TT7R513A4@XW5,])8X@@J5/42\)>`,9M3=^,$
M4TE-8:RFK"F9;4PX5I/`@[42T,P.9`G&$&2N1S;EQ[E?MIW[%&.,HHX/H]NS
M%$,,L7#'UHIT7<+-*4([B80@HN=8,Y4E=@V9&B8R;E!NV=/')D41.*1A'8=F
MQAO"^UF4V^ZU=#^OU`:/1;?:<4E*`X/RDS)).@X2'C&O;[D9S#NYC-104]<;
M+3%9#JV7$(*U%$IE29:2$OMBW\C.\5,`^XSSGL/N'8@DK*&3;)1+%QTR+=,,
MV++U*''#:JG:RT'6W3""L+6(51=^BFH0J12@*!B"8#=#>I3T.5Y+VQQNC[2W
M$,*80Y\ZRU4"G<+@"0%*DI)*9A4IZ&8//3QZA6'8]W,R.L[IVY3S;[J#2..,
MJ?1TYJT2F1`.J3,2(E+2+TV+D[[(5KB7<#"<>ZK?9J235:P]7HO#.WEM<K)+
MIBDQ0A'3;'\.I'2:CHQ`1<B[;>@KVG]4G;W!C)PSOK;ZMIRX7=QFG<<25%VX
MI*!KQ4%.$2'$@@SC,WLE[(5-.6+?;4N51IU;>C1+2H>T\"E`(/QB^GL41,K`
M<%S1\I!3M<<$SUFU1.'LS1\RF&;-:R$.S3>ED4TG"ZY&YRE,K\P*'*80,8>H
MXO\`4"^*KN2J3S=0?DZ=*G4+#B5%+"02%@D'42/G./>[`,FE[>J6EIUEM594
M*0VX"E24ETRW`R(G*>NL;GMS;[;=/U?^G^6VM*Z[9>>WX>/K&ZM=WE+=\?#T
MCP=^^+A1[BKW`+M:BLSH0&<*Y6,GPZX)CZ+B4!@G5K<@FL/RJ*M)6%!<X!U#
MZDN_Z@U]*_IJR5B[=M&*3?NK:!Y3>T"9"3J@D3X$:SCY@?55CJ\?[C5-P"94
MMR;#@5R*AHKD)&?'C'H"]B[-\;E_@^SQ++.$'<_A2;G*%*1ZA@%5:EV51Y/5
M5YZ0CW&:*-WSMF(AT[VA@_#7+GU*6!W'>YGZLR-C=:4/I4-07@/YGWR,=3?3
M#D8R[M,FPOJW55"5L+"M`&5;@B7&>GI**,0K]GXYYN=HLRG1>TRQF6B>X`2"
M:@G2ZR[/<XCLLTE8=3TC=N_:<OQ+K;#M=0]P,(IVB=Z7V`EPRU0\D2D=3*6W
MC&B?TVX=M>X#CC2"VY3OJ4G;J%LJ<)!3PW:$3'KK&\6D7*$OU8BK/7W)'+"3
M1(<X`8!5:+@0OU#-VGOW).&RFY3%'8=MA\!UQC?;766>X.VRJ!34-$A*AJDC
MDH'SCO>PW2CO]K9N5`H+9<2"N?$&6J2/'RB@N2&*Y7-N`,RX=A95C!2>3L:V
M^BQ\Q)(K.HZ)=V6%=Q2+]XV;;.'+=J9SW&(00$Q0$-]7V+WO^W,AH[[LZWRU
M2EPIX3">($6^3V%60XW66)*^E\S2J:!Y`GGXRCXW%O"DA@7C=@S"%BD8BT2^
M)\:52C2,ZQ9'1CI-]`1:#!S(1[5\51RW:N%$1,0AQ[P*.P]=7.89*]D>4W'(
MZ=*D)KZQU[9N*2D.**@DR)!(G+X12Q/&6;#BEML-9TWJF@HFF-Q2%`EM"4DB
M8!D93'_G&0*;5)(HII((H$W`>U$A$P-Y[F`A2AXAK'B\XLA;BB5^9)E\3&4-
MM,L>YE"`HC620(YG3,8`$"E[@$-MQ\`W#?80VZB&J"6TI=ZFI5X^'PB!4YL(
MD->4Q^T@_LB29FB(@/TK0=]^\PHI=P_`=^SJ.JQ>?*Y!:PW+DH\?2+`VR@*T
MJ^6IS,^XE")_;MUB!&1""/:DD3?Q$A"%WV\/`H#L.J/4JU>]Q>Y03HG4"?K,
MS^R+ENCI&5#HLL)('X@A(,_0`1S%OWE[#D()1\0,/<&X&`P#ML&X`(=/AMJC
ML?'\U*RFHV2F/$F9^[2)W&&G067DI<IUF:@?$&8D/(_9$P$CE*!2]ORF*;;?
MQV-N;KMTW#4O04!H9J+B5$^0E/\`88KA7MF``0")<N$AK`4S]P#\H``#^8CT
MV`>@;@&W3X:JK25N(4H>U.Z8GIRD9?;%%*%)"MI&XRD9:\YB?V1,[-P$.TNP
M[AMY=H_$//4\C(!/MEX146E*N(W`B1GX1;FT9(K5-DF<')?=Y";>,EI-O"UF
M`F+'*$BTG(-1D%F4,R>*-F)7!_3!13M`QMP#<0':0H5U"^#)4I%)U!/[T^1^
MV**4*00WH6@9@C20Y)EK,`:3G\(^,EEK&KF.G9>1=JQ0UP\4E-Q]BKDG%3[0
M\X;TX1((9_&DE'QIA?=)J#=-7UE0$A=S@(!6:=J&D!(<<&LS[C(>DI:1*JDI
MEN*6MIHDC0[`3\3SCBWS12OJV;9^TMU<^XNVL:P>VFD6>N1*SYXJ5!BQ"4E(
MQ!@W7>KG!-$JAT^\Y@*'4=4MJD*4M.JE$$ZG7UX_LBXVHDE(`&T2!D-/2.K+
M9HQXBYF6"@6&8-5Y-W%6-2(HMEL3"`D(\"F>(R#IA$.6R1D$5`.(E,;^WU\-
M3H4\@[TK6@RX(5+[Y12?8;>2$J2VHCFM.[[IB)A\QXV;/%&4*65L,@FPB))9
M&FTV=GE48N?CDI:&?K*1,8L1-I(L%B*)F$P=V^VVX#M5<J*A:=JEK4/XE$_Y
MQ*U24[2@M*&PH>"`/\HKBH76NW5J_6@E77JQCT(^7CI&,?0TO%/C().4V\E$
MR;=J^9G6:+$4()B=JA#`8HB&J(+BB"Y*8X15#3:00V``KB(K+;_AMJ;2(RY\
MY2C2G[VO#E_R7XQ%R+1(M24RIQZ<R5TAV+)J"\G8Z,\;IHWVMM"%*51PZ(S:
MI2+5/NV,LS$@!NH&M]?3;GZL*S--+7$?I%R2&3,@!*R?8LST_A]2(YS^IOM\
MG.L"<KJ-/_ZMK47M`25-R.Y(D)G@#+R,><3VL>7+GB#GJO6^467'&=Q;EI^4
M6B2AA2"MNG*:C"Q)I;&*L]J3XQ70```8R!UB@.RA=NO^^W;]G-<5^382%7RB
M!=96-9I`]P)UT5R\8Y3^G_-'<)NR*E9E:ZQ1;?1S!4?:9>(/V<X]DF?\.Q>;
MJM!9!H;N/DY]I$MW\"_:+(J,[=67B))%%LB^3[B&,=)45F:P#V]QA*/0W3@[
M`<SJ\)K7;/7[OE:AX[@H'^6X#(GRTT,=N]R,$8S*WLWJV%)N%,UH1^=LCA,<
M3K,1B]AZ_6;%4RX3117%@NO]/-5Q\(HBL=J?L[Q2,'^@E&X`(".WS>!MPUM;
M*L>MF6-=5@H^8V3"P0>(X3&A'B(U+B&1UF(.IIZ<+-M+H#B5`@[YR,@1.7I&
MRFGY`KES;)N(IZ4CD2[KQ;HOT[]L8`^8JB)A^;8=]A+N40US?=K-5V>L+#P)
M`/$3*3YSCJ*SWJEN]&*A!"5'D2)_9%=@("`=?+^.K&/4!'"8G$=](3$-(C.&
MD(:0AI"&D(:0AI"+$6>`O$'E,,AU*OQEM92E)94Z6B',ZG7)"/5CIU_-,Y)D
M[=,G3)VV7"1.FJG\BA3$`P;^&D(IRQ53+%[92,I(0-0K4A"6+'MDIE?5EC2S
MF1<TN86F9%M9[,PCT/2:R@+`DS(FFL5J<HJ&W[Q#2$=VYL,J9,AD*?(T*)J$
M4]GJS(R\ZYNK6;4;1]=L4785D6$;'Q:2KEZ]-%E13[S$3+WB8W@&D(KG'50D
M:^CD-.:(T52M.1[=9V2:9_6(>&FRM4FA7.Z:9B+F20,4Y/F[0Z`(AI"+.U@U
MLJ.6LP1]#Q_&SE=01QC'-VA)Y.J#%)Q],3(U09E>1SEH^CB(&`@>D<#)&*)1
M+U$=(1='&]8M#*QY"N]MCX^$D;Y*5Q1&OQLG]Y)%L:U!I0K=1U)_2,4G+U^I
MWJ&!,G:0@$+U'?2$7ETA'672]9(R0E()3AVJ$4+W$43$-CD$-A`0.`[==2R4
MA25LG:M)F(E6AAU*V:A.YE:9$<M?\<(\C/NA^V1)X`O$[R)P;`K/<&6J25F+
MI6(AN9=7$]DDE3F?/R,"IJ$-C^6?./6*<I.V.6,*9^U$2&#N#M%WJ3?:"GQ3
M*:DLUS$PAXG6H1H$(4?%(TUX\><HXC[K]G4XO<UY/C+!7;GE`]-(GTU_F4?(
MG6<7$]M'W(G&!F$?AG-3M[*X=56+^TK(0%GDEC8[U4PJM5T#&%=_3%SF$X$1
M`56)NXR93)F["^=WB[/MY!4*R"PA#5U)F6@9)>2!Q\-W,3X\^1&;=KNXM7;6
MTV>]'^EV"1_=)(F/_"/15,4#&V:(F/N]:DHYQ]X9HNXBW5UPU?LI9HKL=(5Q
M2.9N_2,4.NXE4+U`1`0V#EZV9'?<3J7+;6MJ3M)"VE@@#S$^!Y^>DHWI<L8L
M>1L"NIBGKJ$PH'GX_;%N@PQ;()P'T)6LB@D;=-RP<G07+MX&]$ZB"B2OX%.)
M=9$,QM-P']2B4XQ<X;=J$SIES](N;`%R"P*1%4LHHF4"D[7A4G!@`H;;=YQ.
M<=MO(P:\2L58GU*<24@$S$M(R&B3>&4):6%%:1(GQ,7+8A8EP*+M0K8FP=PG
M22!3?8/`I1-L'YZQ^I^32O\`I]4_&,CIC5%!^9F%3TBID2B0``3F4';J8VVX
MCYCY=-6"S/E*+YH25'8U3BZAI"&D(:0AI"&D(:0AI"&D(:0B61,"F,?M*!C[
M=P@`;CV]`[C=H"?8!\_#RTA$S2$-(1#8-2%M"CN(U@-!(<(^?(QS&4:/6$BS
M:2#"0:+,GS%\@FZ9O6;A(Z+AH[;+%.BX;KI*&*<A@$IBB("&@6MEU#E,5)?;
M5,$$@CS!\8I.,MOI6U4A*J=8D00"/OC1=RG]GV'EY:1R!Q:=L*G(.E%WS_%$
MPHJVK"[E0PG54J$T`J*5]543F$C58#-"G'Y#)%';71N(=]JZF:;MN6!=0R@`
M)>`$T@?O@#4`<QJ3QC264]H*):OG<>VH)65=.9E,@\"3/CRG&#V,KYRUX06,
MT*Y86RBMO6$[VGVZ.<R%'F`*8I3JMBJ*GB5!4#]+E@[3..^XF'PULF_6S!.Y
M%*AY#E.\\H"2FCM<;)X%6L].84/A&,6FY9;B=2EBL0\AA*Q-,II4`=1J#IY@
M^D;9<5^Y_6[$V:H9#Q]+PS\Z>SB1J+IM-Q1C%``%0K!\HS?(B(]1*!UMO(1\
M](7[LQ<*1Y2K-4)<9Y!<A+U(X_8(VE0]Q*5T`5C*D>,9;0O,;`LRD0R5K>MC
M'*4P)/J],('*)@`>PWIM%"]Q?/8=M8:_V]RVG!ZS""@<"#H?,&?",@9RRR.D
M+2XL`\I14[;D-C^46(WKGWVQNEAV1;14*Z'U5/(IE%RIE3`?^[;5DK&*^F2?
MF.DV!QFK7U$>DW>[?5_[,URTG+A%RHA]:)SL<.HL*NQ.`""+E5-W,*EVZ@9-
M(1;LQ'\SF#X:\:I12,CIH<*WY\@-OGZQ?-^X[P))\(K)%,$B`0-_'<PB83B8
MWF83&`-Q'\M6<5XFZ0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0C@;SWVVZ>.
MJ:]W_:_W8D5+_N?@B0/9W$WWW[OE[?#?;S_#;1/S6WW[?\>,6ROE>HG\4]VG
MA.*<M/[3^T._WM]A_;_S?6?NC[9]H[.WYO7^[?Z/L\?U:BQ^H=='R/7ZFX?[
M,Y\?S2UEXQ6K?E>C_5]+I[?S2^Z?.,'[-_\`75]<Y^Y_[-_7^H?U_P!N=WJ^
MMOU_^,_VN_?_`*>FMF47_)O1/Z=\S*7Y]LO_`'1B55_9LOY_2^$?1J'_`((>
ML7[%^RN_U`[?N?W[T>_;Y>[[O_:V^&_3?4:S_DSY<?J/7X>Z6R7G*7*+FE_M
MN0Z'2Z4M/3E&8M5_9'TJ?[*_;7T/83_V#[?Z?9VAV=_T7S_IV_7UVU@=9\[U
MOZWK=7SG+XST^R/>I_TK;_(Z<_X9??%9AXAMX;?UVU9&7/C%<2W^S\$3-0BK
;#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA'__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
